LCD L39396: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin — Noridian
Policy LCD-L39396 · Hematology
New LCD requires billing team review.
Code intelligence
C81.90 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code C81.90.
Normal code riskView ICD-10 detail
Signal breakdown
3 shown · 3 total in platform
Risk: Normal
0
Critical
0%
0
High
0%
3
Routine
100%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
Routine
LCD L38645: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells — Noridian
Policy LCD-L38645 · Oncology
New LCD for circulating tumor cells affects oncology billing.
LCD L38822: MolDX: Minimal Residual Disease Testing for Cancer — CGS
Policy LCD-L38822 · Oncology
Prepare for new billing guidelines in oncology testing.
Audit documentation
Building an audit file that includes C81.90?
The Tripwire Audit Pack exports 12 months of Hematology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Hematology audit pack — $349One-time purchase · not a subscription